JP2020534017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534017A5 JP2020534017A5 JP2020516818A JP2020516818A JP2020534017A5 JP 2020534017 A5 JP2020534017 A5 JP 2020534017A5 JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020534017 A5 JP2020534017 A5 JP 2020534017A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- composition
- antigen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023103361A JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2024215117A JP2025061650A (ja) | 2017-09-23 | 2024-12-10 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562374P | 2017-09-23 | 2017-09-23 | |
| US201762562373P | 2017-09-23 | 2017-09-23 | |
| US62/562,374 | 2017-09-23 | ||
| US62/562,373 | 2017-09-23 | ||
| PCT/US2018/052253 WO2019060750A2 (en) | 2017-09-23 | 2018-09-21 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103361A Division JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534017A JP2020534017A (ja) | 2020-11-26 |
| JP2020534017A5 true JP2020534017A5 (enExample) | 2021-10-28 |
| JP7303802B2 JP7303802B2 (ja) | 2023-07-05 |
Family
ID=65810903
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516818A Active JP7303802B2 (ja) | 2017-09-23 | 2018-09-21 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2023103361A Pending JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2024215117A Pending JP2025061650A (ja) | 2017-09-23 | 2024-12-10 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103361A Pending JP2023138957A (ja) | 2017-09-23 | 2023-06-23 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
| JP2024215117A Pending JP2025061650A (ja) | 2017-09-23 | 2024-12-10 | Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11555072B2 (enExample) |
| EP (1) | EP3684369A4 (enExample) |
| JP (3) | JP7303802B2 (enExample) |
| KR (1) | KR102783937B1 (enExample) |
| CN (1) | CN111372590A (enExample) |
| AU (2) | AU2018338322B2 (enExample) |
| CA (1) | CA3076611A1 (enExample) |
| IL (1) | IL273484B2 (enExample) |
| WO (1) | WO2019060750A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| US11122038B1 (en) * | 2017-05-18 | 2021-09-14 | United Services Automobile Association (Usaa) | Methods and systems for authentication of new users |
| CN113573782B (zh) | 2018-12-21 | 2025-12-16 | Ose免疫疗法公司 | 针对人pd-1的双功能分子 |
| US20220056135A1 (en) | 2018-12-21 | 2022-02-24 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| AU2019406452B2 (en) | 2018-12-21 | 2021-09-16 | Ose Immunotherapeutics | Humanized anti-human-PD-1 antibody |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CA3136251A1 (en) | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| US20230365636A1 (en) | 2020-11-16 | 2023-11-16 | Technische Universität München | Bioorthogonal reporter gene system |
| AU2021381768A1 (en) * | 2020-11-18 | 2023-06-22 | Memorial Sloan Kettering Cancer Center | Anti-gpa33 multi-specific antibodies and uses thereof |
| CN116744981A (zh) * | 2021-01-13 | 2023-09-12 | 豪夫迈·罗氏有限公司 | 组合疗法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| WO1994013805A1 (en) * | 1992-12-10 | 1994-06-23 | Celltech Limited | Humanised antibodies directed against a33 antigen |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO1999055369A1 (en) * | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| CA2579391C (en) * | 2004-09-06 | 2010-10-26 | Kirin Beer Kabushiki Kaisha | Anti-a33 antibody |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| CA2959436A1 (en) | 2014-09-30 | 2016-04-07 | The Medical College Of Wisconsin, Inc. | Universal platform for targeting therapies to treat neurological diseases |
| WO2016130539A2 (en) * | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| SG11201708257UA (en) | 2015-04-06 | 2017-11-29 | Subdomain Llc | De novo binding domain containing polypeptides and uses thereof |
-
2018
- 2018-09-21 IL IL273484A patent/IL273484B2/en unknown
- 2018-09-21 EP EP18859251.3A patent/EP3684369A4/en active Pending
- 2018-09-21 JP JP2020516818A patent/JP7303802B2/ja active Active
- 2018-09-21 CN CN201880075541.7A patent/CN111372590A/zh active Pending
- 2018-09-21 KR KR1020207011796A patent/KR102783937B1/ko active Active
- 2018-09-21 CA CA3076611A patent/CA3076611A1/en active Pending
- 2018-09-21 WO PCT/US2018/052253 patent/WO2019060750A2/en not_active Ceased
- 2018-09-21 AU AU2018338322A patent/AU2018338322B2/en active Active
- 2018-09-21 US US16/649,617 patent/US11555072B2/en active Active
-
2023
- 2023-06-23 JP JP2023103361A patent/JP2023138957A/ja active Pending
- 2023-11-03 US US18/501,782 patent/US20240327511A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215117A patent/JP2025061650A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204844A patent/AU2025204844A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| ES3003809T3 (en) | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| CN108124445B (zh) | Ctla4抗体、其药物组合物及其用途 | |
| CN110214152B (zh) | 模块化四聚体双特异性抗体平台 | |
| KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
| TWI742054B (zh) | Ｇｉｔｒ抗體，方法及用途 | |
| JP7450585B2 (ja) | ＣＤ６６ｃに特異的に結合する抗体およびその用途 | |
| JP2020523029A5 (enExample) | ||
| JP2023537002A5 (enExample) | ||
| JP2022525435A5 (enExample) | ||
| JP2022546572A5 (enExample) | ||
| WO2022161425A1 (zh) | 抗tnfr2人源化抗体及其用途 | |
| JP2022538117A5 (enExample) | ||
| JP2021521245A (ja) | キレート化された放射性核種に対する抗体および除去剤 | |
| CN117343193A (zh) | 双特异性抗体及其制备和使用方法 | |
| EP4238990A1 (en) | Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof | |
| JP2021517816A5 (enExample) | ||
| JP2022531229A (ja) | 併用治療 | |
| CN118339187A (zh) | 抗pd-1抗体及其用途 | |
| JP2024534550A5 (enExample) | ||
| CA3107524C (en) | Humanized Monocolonial Antibody Against CTLA4: Preparation Method and Application | |
| US20260028402A1 (en) | Anti-cd100 antibody and use thereof | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| WO2019197974A1 (en) | Anti-telomerase reverse transcriptase antibodies and use thereof |